Post-Infectious Disorders

Debilitating disorder characterized by fatigue and other symptoms related to cognitive, autonomous, and immune dysfunction experienced in the aftermath of infections.

Also Known As:

Post Infection Syndrome; Post Infectious Disease Syndrome; Post Infectious Disorder; Post-Infection Syndromes; Post-Infectious Disease Syndromes; Post-Infectious Disorder; Syndrome, Post-Infection; Syndrome, Post-Infectious Disease; Post Active Phase of Infection Syndrome; Post Infectious Disorders; Post-Infection Syndrome; Post-Infectious Disease Syndrome

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Disease Context: Research Results

Signs and Symptoms Pathological Conditions
- Pathologic Processes: 10023
  - Disease Attributes: 18
    - Chronic Disease: 25762
      - Post-Infectious Disorders: 2
        Guillain-Barre Syndrome: 3714
        Reactive Arthritis: 1294
        Post-Acute COVID-19 Syndrome: 750
        Acute Disseminated Encephalomyelitis: 530
        Post-Lyme Disease Syndrome: 130

Related Diseases

1.	Inflammation (Inflammations)
2.	Campylobacter Infections (Campylobacter Infection)

Experts

1.	Ardid, Denis: 1 article (01/2022)
2.	Barnich, Nicolas: 1 article (01/2022)
3.	Baudu, Elodie: 1 article (01/2022)
4.	Bonnet, Mathilde: 1 article (01/2022)
5.	Borras Nogues, Esther: 1 article (01/2022)
6.	Carvalho, Frédéric Antonio: 1 article (01/2022)
7.	Chatel, Jean-Marc: 1 article (01/2022)
8.	Daugey, Valentine: 1 article (01/2022)
9.	Defaye, Manon: 1 article (01/2022)
10.	Delbac, Frédéric: 1 article (01/2022)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Post-Infectious Disorders:

1.	VaccinesIBA 01/01/2020 - "Our work emphasizes the potential of FliD as a target for the development of vaccines and supports the concept that orally administered FliD-reactive SIgA can be developed to prevent or mitigate the severity of Campylobacter infections as well as the development of post-infection syndromes."
2.	Secretory Immunoglobulin A (SIgA)IBA 01/01/2020 - "Our work emphasizes the potential of FliD as a target for the development of vaccines and supports the concept that orally administered FliD-reactive SIgA can be developed to prevent or mitigate the severity of Campylobacter infections as well as the development of post-infection syndromes."
3.	Volatile Fatty AcidsIBA 01/01/2022 - "These post-infectious disorders were associated with low-grade inflammation, increased intestinal permeability, decrease of Lactobacillaceae abundance associated with the colonic layer, and increase of short-chain fatty acids (SCFAs). "